Impression Healthcare Granted Permission to Conduct Phase 2A Trial of CBD for Gum Disease

Melbourne-based, innovative healthcare company, Impression Healthcare LTD, has supposedly gotten the green signal to conduct a Phase 2a Clinical trial in Australia. The trial will serve as an investigation to assess the overall safety and effectiveness of cannabidiol (CBD) in treating gum disease reports Ganjapreneur.

A Phase 2A clinical trial is simply a placebo and controlled groups trial, where the former consists of individuals who are either given nothing or something with no effect and the controlled group takes CBD. This type of a trial is typically preferred to evaluate a drug’s overall safety and effectiveness.

As for this study, Impression Healthcare LTD partnered with Cannvalate, a provider of medical cannabis related services, back in March of 2019 to undertake four medical cannabis trials. In addition to the one studying the effects of CBD on gum disease, the remaining three are investigating the former’s effect on sleep apnea, concussions, and TMJ Dys (Temporomandibular Joint Dys).

According to the team at Impression Healthcare LTD, the trial will, “examine the benefits of Cannabidiol (CBD) Mouthwash and Toothpaste to reduce the grading of Periodontitis compared to a placebo,” as reported on the official website. They also believe CBD’s ability to suppress inflammatory processes while preventing cytokines is what makes the compound a candidate for testing.

Another party involved in this endeavor is AXIM Biotechnologies Incorporated, who will be the ones to provide the necessary products for the trials, while “facilitating commercial sales under royalty arrangement.”

According to the CEO of Impression Healthcare LTD, Joel Latham, the approval is indicative of the interest garnered in medical cannabis and he has since expressed excitement in the works to come.

In particular, he was referenced saying:

“We are excited to have assembled highly qualified researchers for a world first trial for the use of CBD in treatment of Gingivitis and Gum Disease, which are major problems representing a major market.”

Moreover, Latham is confident that the trial will open up new opportunities within this respective field, especially in the form of viable, CBD solutions.